In launching epinephrine nasal spray, ARS Pharma has a 'blue sky opportunity,' analyst says

Gaining FDA approval for its epinephrine nasal spray came nearly a year later than expected for ARS Pharmaceuticals. But after the recent approval of neffy, the San Diego drugmaker is poised for an October launch and a “blue sky opportunity,” according to analysts at Leerink Partners.